{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"The maximum tolerated dose is defined as the highest dose level of nivolumab with \\< 2 out of 6 patients experiencing a dose limiting toxicity during the first 28 days of treatment. The starting dose level for Azacitidine is 75 mg/m\\^2 and the starting dose level for Nivolumab is 3.0 mg/kg.","groups":[{"description":"Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nNivolumab: Given IV","id":"OG000","title":"Arm 1 A Lead-In (Azacitidine, Nivolumab)"},{"description":"Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nIpilimumab\n\nNivolumab: Given IV","id":"OG001","title":"Arm 2 A Lead-In (Azacitidine, Nivolumab, Ipilimumab)"},{"description":"Patients will receive therapy with nivolumab IV infusion on Day 8 and Day 22 (+/-3 days) of each 5-azacyidine cycle for first 4 cycles or until CR (whichever occurs earlier) followed by a maintenance regimen (one dose of nivolumab on Day 8 of each cycle of 5-azacytdine). Venetoclax will be administered orally daily on Days 1-21 of the first cycle; and Days 1-14 or Days 1-21 for subsequent cycles.\n\nAzacitidine: Given SC or IV\n\nVenetoclax: Given Orally\n\nNivolumab: Given IV","id":"OG002","title":"Arm 3 A Lead-In (Azacitidine, Nivolumab, Venetoclax)"}],"paramType":"NUMBER","populationDescription":"All participants were treated at dose level 0, the starting dose.","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"Maximum Tolerated Dose of Nivolumab in the Combination of Nivolumab With Dihydro-5-azacytidine","type":"PRIMARY","unitOfMeasure":"mg/kg"}